- Home
- CMMB vs FLUX Comparison
CMMB vs FLUX Comparison
Compare CMMB & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- FLUX
- Stock Information
- Founded
- CMMB 2004
- FLUX N/A
- Country
- CMMB Israel
- FLUX United States
- Employees
- CMMB N/A
- FLUX N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- FLUX Industrial Machinery/Components
- Sector
- CMMB Health Care
- FLUX Miscellaneous
- Exchange
- CMMB Nasdaq
- FLUX Nasdaq
- Market Cap
- CMMB 22.0M
- FLUX 25.4M
- IPO Year
- CMMB N/A
- FLUX N/A
- Fundamental
- Price
- CMMB $0.95
- FLUX $1.67
- Analyst Decision
- CMMB Strong Buy
- FLUX Strong Buy
- Analyst Count
- CMMB 2
- FLUX 2
- Target Price
- CMMB $8.50
- FLUX $6.00
- AVG Volume (30 Days)
- CMMB 125.0K
- FLUX 81.3K
- Earning Date
- CMMB 08-20-2025
- FLUX 08-19-2025
- Dividend Yield
- CMMB N/A
- FLUX N/A
- EPS Growth
- CMMB N/A
- FLUX N/A
- EPS
- CMMB N/A
- FLUX N/A
- Revenue
- CMMB N/A
- FLUX $63,074,000.00
- Revenue This Year
- CMMB N/A
- FLUX $11.10
- Revenue Next Year
- CMMB N/A
- FLUX $12.66
- P/E Ratio
- CMMB N/A
- FLUX N/A
- Revenue Growth
- CMMB N/A
- FLUX N/A
- 52 Week Low
- CMMB $0.87
- FLUX $1.15
- 52 Week High
- CMMB $2.55
- FLUX $3.64
- Technical
- Relative Strength Index (RSI)
- CMMB 17.79
- FLUX 46.86
- Support Level
- CMMB $0.87
- FLUX $1.42
- Resistance Level
- CMMB $1.01
- FLUX $1.69
- Average True Range (ATR)
- CMMB 0.06
- FLUX 0.16
- MACD
- CMMB -0.01
- FLUX -0.03
- Stochastic Oscillator
- CMMB 23.78
- FLUX 34.25
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.